While 90 may not be the new 40, it may become the new 75 or 80 as science, technology and policies converge to leverage the gains from the genomics revolution, which are making precision medicine a clinical reality.
As clinical stage biotech and pharmaceutical firms face unprecedented challenges in raising capital to fund their clinical trial program, strategic trade-offs are coming fast and furious. One of those at the top of the list is when and how to build a commercialization strategy, including navigating the complex work of securing market access.
Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.
Lumanity today announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life. Lumanity CEO Jon Williams says, “We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, today unveiled EVERSANA INTOUCH, marking the transformation of its full-service, global healthcare agency network serving the life sciences industry. Combining the power of world-class creative, media and digital innovation with payer, patient, and healthcare communications expertise, EVERSANA INTOUCH reinvents life sciences marketing as the first and only agency accelerating brand performance through insights and seamless connectivity to EVERSANA’s integrated commercialization solutions.